Insider Buys 22k Options at Cabaletta Bio as SLE & RA CAR‑T Trials Show Promising 58% Response
Insider confidence in Cabaletta Bio’s T‑cell therapies signals potential upside as the company nears pivotal Phase III trials and regulatory approvals for SLE and RA treatments.
4 minutes to read